Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Boehringer Ingelheim Gambles $2.62 Billion on Two Fibrotic Disease Deals

South Korea-based Bridge Biotherapeutics licensed out BB-877 to Boehringer Ingelheim for a total deal of about $1.75 billion, marking the second large transaction for fibrotic diseases that the Germany-based company inked during July 2019.

Read More »

Merck to Acquire Tilos Therapeutics

Merck agreed to acquire Tilos, a privately held biopharma company developing therapeutics targeting the latent TGFβ complex for the treatment of cancer, fibrosis and autoimmune diseases.

Read More »

Morphic and Janssen Strike Potential $750 Million Deal

Morphic Therapeutic and J&J division Janssen Biotech entered into a collaborative deal to develop novel integrin therapeutics for conditions not adequately addressed by current therapies.

Read More »

Gilead Inks $785 Million Deal With Yuhan

Gilead Sciences Inc. is acquiring the global rights to develop and commercialize novel small molecules against two targets from South Korea-based Yuhan Corporation.

Read More »

AbbVie Invests $100 Million in Morphic Therapeutic to Develop Integrin Inhibitors for Fibrotic Diseases

Weeks after Waltham, Mass.-based Morphic Therapeutic secured $80 million in Series B financing that was supported in part by AbbVie Ventures, the company struck a deal with the pharma giant to collaborate on the development of therapies for fibrosis-related indications.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom